MedTrace Logo

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

NCT03248531 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-04-11

Study results available
· View outcomes & findings →

Summary

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

Conditions

Interventions

DRUG

Bimekizumab

Bimekizumab in different dosages (dose 1 and 2).

DRUG

Adalimumab

Adalimumab in different dosages (dose 1, 2 and 3).

OTHER

Placebo

Placebo will be provided matching Bimekizumab.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · +1-844-599-2273 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2018-11-23
Completion
2019-02-21
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Denmark
  • Germany
  • Greece
  • Norway
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03248531 on ClinicalTrials.gov